Vectura Takeover Rumours (VEC)

Vectura Chart

Vectura Takeover Price

Vectura Takeover Forum Posts

13-10-2019
Agree. Nothing of substance and the share price has gone nowhere but down for years now. GSK, Sosei and probably Hikma have all made enquiries over a takeover IMO and the rumours from The Telegraph re:GSK 175p/share last year were probably not wide of the mark yet we remain in the dark over what offers were made/what really happened.
12-10-2019
The board must disclose any offer received as per FCA rules. Most here I am sure would much prefer a good swift takeover offer actually as the SP has been kept in lockdown for years now.
11-10-2019
Great to see you buying more following your essentially private audience with The Board -presumably they are confident about- -Advair Generic -Elipta Generics -Payment by GSK re law suits -New product developments -Exparel final milestone of $32mill in next year or so -Profitability following reduced R & D spend -new CEO appointment -expected value should takeover discussions arise -potential for increasing share buy backs as our cash pile grows
13-09-2019
While Some aspects favour a GSK Takeover With Vectura having tied up with Hikima with the Ellipta generics can’t imagine they would be happy with GSK as a partner so we could get a counter bid in my opinion which would be great for us
10-09-2019
GBCol-they have been looking for a partner for quite some time so not optimistic. Recent research efforts have been failures or had significant knock backs such as Advair generic. This company is based on Flutiform as it was three years ago, no sign of things changing at the moment, the takeover has been a disaster so far for ex SKP holders like me.
08-08-2019
Fhm as you know up until the takeover Louise wasn’t actually flavour of the week with many on the BTG thread calling for her to resign.
02-08-2019
Most takeovers happen out of the blue on the back of few if any rumours. Shell and BG Group comes to mind. Sainsburys-Asda merger another. Takeda-Shire reverse takeover came out of the blue also. There have been no M&A rumours with Vectura for 1-2 years now despite the recent court ruling award. After another crap week and finish here long term holders live on in hope.
25-07-2019
Always so disappointing that we cannot ever keep hold of the gains............takeover please to put us out of our misery..!
Ah the vacancy who are they going to get who has a very good reputation and well paid join VEC with the chance of a takeover however remote and be out on their ear in a year. justfor the problem is no ones buying as simple as that i don't think there is any conspiracy here, just no ones buying as always could well be wrong.Numbers being traded is small very small. A
19-07-2019
I would like the GSK case to be over and for VEC to receive a big chunk of money but my main concern is lack of new money making treatments. In the three years since the takeover there has been little or no money making developments. Polaris may well be right that the Hikma deal may lead to riches in the future but hard to see how the board have justified their salaries in the last three years.
17-07-2019
I agree guys but with view to Vec being a serial underperformer since my SKP shares were acquired I am interested in seeing the strategy of our new CEO ,when eventually appointed .A CEO with a strong track record of building growth companies would be viewed as a positive -especially as we could have £200mill in the bank .Not sure who has the authority to sanction a £50 mill buy back when our Board currently consists of a CFO (currently interim CEO) & nom exec Chairman.Perhaps a takeover for a ‘fair’price will be the best outcome for all stakeholders
30-06-2019
My reasoning was the current valuation of Vec if GSK lose the case along with Uk appeal you are looking at around 50% of the current market cap in damages or more then they look at the potential risk to the Ellipta range and it becomes very attractive to GSK. Then we have the strong chance that Hikima would not be happy with GSK as a partner so along comes the counter bid.I would also see Hikima making a takeover approach if they start to see the right data from the Ellipta trial similar thing happened when SKP fluitform partner tried a sneaky approach but they didn’t quite have the cash to take it private but no worries on that front with a Hikima. But looking to the here and now the chart looks very bullish to me signalling a 90p breakout this week.
28-06-2019
Would VEC's various partners in other projects be happy to see a GSK takeover? If not, then what?
10-06-2019
Just musing, but if a takeover was being considered, perhaps Lilley may have seen the writing on the wall for him, and went now rather that after a takeover. He probably will go with a lucrative golden goodbye as well.
I got the feeling Lilley as CEO was blocking a takeover and found advances and potential offers/rumours 'unwelcome and 'unhelpful'.. Perhaps another reason why he has left/resigned? Sosei rumour, GSK 175p/share and others...
29-05-2019
If only the company were as good at drug development as they are at presentations and managementspeak. In the three years since the takeover/merger we have heard very little good news and lots about failure and delay. The most important news was the Ellipta deal with Hikma but it will be quite some time before that generates significant revenue.
24-05-2019
base7 & others-not sure VEC can make an offer to buy HBM shares without making the same offer to all shareholders. VEC can choose to spend some of their cash pile buying shares in the market via a third party as before. They have said that they have cash surplus to operational requirements so I cannot understand why they are not using some of it to buy shares while the SP is under pressure due, in part, to HBM selling. I am not sure whether my glass is half full or half empty as I have lost a lot of money since the takeover of SKP by VEC but am still showing a healthy profit overall as I bought my SKP shares a long time ago.
21-05-2019
Interesting to see a lot of broker comments about Vectura being a stand out takeover candidate in light of the court news......
28-04-2019
Even though rules dictate companies must declare all offers and approaches in practice I am sure there are exceptions. Vectura being a highly probable example. The GSK rumours reported by The Telegraph, Zak Mir reiterating the same shortly after and then Sosei's bizarre RNS denying any takeover interest did have some substance IMO. However sometimes the board prefer to stay on in their highly paid jobs and continue receiving their bumper bonuses. Indeed the CEO here felt the takeover rumours were 'unhelpful' and sadly probably 'unwelcome'?
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191018 22:09:37